Cargando…

Prognostic Significance and Treatment Implications of Minimal Residual Disease Studies in Philadelphia-Negative Adult Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia (ALL) is curable in about 40–50% of adult patients, however this is subject to ample variations owing to several host- and disease-related prognostic characteristics. Currently, the study of minimal residual disease (MRD) following induction and early consolidation thera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spinelli, Orietta, Tosi, Manuela, Peruta, Barbara, Guinea Montalvo, Marie Lorena, Maino, Elena, Scattolin, Anna Maria, Parolini, Margherita, Viero, Piera, Rambaldi, Alessandro, Bassan, Renato
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165493/ https://www.ncbi.nlm.nih.gov/pubmed/25237475 http://dx.doi.org/10.4084/MJHID.2014.062

Ejemplares similares

Immature Immunoglobulin Gene Rearrangements Are Recurrent in B Precursor Adult Acute Lymphoblastic Leukemia Carrying TP53 Molecular Alterations
por: Salmoiraghi, Silvia, et al.
Publicado: (2020)

Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia
por: Bassan, R, et al.
Publicado: (2014)

MRD-Based Therapeutic Decisions in Genetically Defined Subsets of Adolescents and Young Adult Philadelphia-Negative ALL
por: Tosi, Manuela, et al.
Publicado: (2021)

Modern Immunotherapy of Adult B-Lineage Acute Lymphoblastic Leukemia with Monoclonal Antibodies and Chimeric Antigen Receptor Modified T Cells
por: Maino, Elena, et al.
Publicado: (2015)

Capture-Based Next-Generation Sequencing Improves the Identification of Immunoglobulin/T-Cell Receptor Clonal Markers and Gene Mutations in Adult Acute Lymphoblastic Leukemia Patients Lacking Molecular Probes
por: Cavagna, Roberta, et al.
Publicado: (2020)

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913
por: Chiaretti, Sabina, et al.
Publicado: (2020)

Burkitt lymphoma in adolescents and young adults: management challenges
por: Dozzo, Massimo, et al.
Publicado: (2016)

Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18–65 years: NILG ALL 10/07
por: Bassan, Renato, et al.
Publicado: (2020)

Highly aggressive T-cell acute lymphoblastic leukemia with t(8;14)(q24;q11): extensive genetic characterization and achievement of early molecular remission and long-term survival in an adult patient
por: Parolini, M, et al.
Publicado: (2014)

Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia‐positive acute lymphoblastic leukaemia
por: Ansuinelli, Michela, et al.
Publicado: (2021)

Next‐generation sequencing for BCR‐ABL1 kinase domain mutations in adult patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A position paper
por: Soverini, Simona, et al.
Publicado: (2020)

A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia
por: Bassan, Renato, et al.
Publicado: (2019)

Integration of Next-Generation Sequencing in Diagnosing and Minimal Residual Disease Detection in Patients With Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
por: Sherali, Nazleen, et al.
Publicado: (2020)

Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease
por: Maurillo, Luca, et al.
Publicado: (2019)

Minimal Residual Disease at First Achievement of Complete Remission Predicts Outcome in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
por: Zhang, Mingming, et al.
Publicado: (2016)

Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study
por: Bassan, Renato, et al.
Publicado: (2019)

Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges
por: Soverini, Simona, et al.
Publicado: (2019)

Blinatumomab vs historic standard‐of‐care treatment for minimal residual disease in adults with B‐cell precursor acute lymphoblastic leukaemia
por: Gökbuget, Nicola, et al.
Publicado: (2020)

Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies
por: Cazzaniga, Giovanni, et al.
Publicado: (2018)

Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1‐JAK2 positive myeloid sarcoma and acute B‐lymphoblastic leukemia
por: Rizzuto, Giuliana, et al.
Publicado: (2022)

Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia
por: Kruse, Aaron, et al.
Publicado: (2020)

Diagnosis and Subclassification of Acute Lymphoblastic Leukemia
por: Chiaretti, Sabina, et al.
Publicado: (2014)

Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial
por: Bassan, Renato, et al.
Publicado: (2023)

Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood
por: Koo, Hong Hoe
Publicado: (2011)

Association of minimal residual disease with clinical outcomes in Philadelphia chromosome positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era: A systemic literature review and meta-analysis
por: Zhang, Wanhua, et al.
Publicado: (2021)

Molecular Detection of Minimal Residual Disease before Allogeneic Stem Cell Transplantation Predicts a High Incidence of Early Relapse in Adult Patients with NPM1 Positive Acute Myeloid Leukemia
por: Lussana, Federico, et al.
Publicado: (2019)

National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?
por: Lussana, Federico, et al.
Publicado: (2020)

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances
por: Della Starza, Irene, et al.
Publicado: (2019)

Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia: Egyptian Experience
por: Ibrahim, Rasha Ibrahim, et al.
Publicado: (2022)

Monosomal karyotype in Philadelphia chromosome-negative acute lymphoblastic leukemia
por: Kenderian, S S, et al.
Publicado: (2013)

Uterine relapse of Philadelphia chromosome-negative acute lymphoblastic leukemia
por: Kawano, Noriaki, et al.
Publicado: (2020)

Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults
por: Saleh, Khalil, et al.
Publicado: (2022)

Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to the age of 60 years with Philadelphia chromosome-negative acute lymphoblastic leukemia
por: Geyer, Mark B., et al.
Publicado: (2020)

Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome–positive B‐precursor acute lymphoblastic leukemia
por: Rambaldi, Alessandro, et al.
Publicado: (2019)

Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia
por: Rocha, Juliana Maria Camargos, et al.
Publicado: (2016)

Sources of error in measurement of minimal residual disease in childhood acute lymphoblastic leukemia
por: Latham, Sue, et al.
Publicado: (2017)

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Current Practice and Future Directions
por: Contreras Yametti, Gloria Paz, et al.
Publicado: (2021)

Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia
por: Della Starza, Irene, et al.
Publicado: (2023)

Is There a Role for Minimal Residual Disease Monitoring in Follicular Lymphoma in the Chemo-Immunotherapy Era?
por: Gritti, Giuseppe, et al.
Publicado: (2017)

Practical guidance for the management of acute lymphoblastic leukemia in the adolescent and young adult population
por: Carobolante, Francesca, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qmi9aq3fttgvrqekg3feecm9h8